Meeting
2024 ASCO Annual Meeting
TAZNI: A phase I/II combination trial of tazemetostat with nivolumab and ipilimumab for children with INI1-negative or SMARCA4-deficient tumors.
Authors
Joanna S. Yi
Baylor College of Medicine, Houston, TX
Joanna S. Yi , Jeffrey Czaplinski , Ketki Bhushan , Suzanne J. Forrest , Neerav Shukla , Stephen C. Mack , Andrew Lee Hong , Alex Kentsis , Mackenzie Stinehart , Suzanne Ezrre , Marylynne Strachan , Steven G. DuBois , Wendy B London , Susan N. Chi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT05407441
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS10077)
DOI
10.1200/JCO.2024.42.16_suppl.TPS10077
Abstract #
TPS10077
Poster Bd #
444a
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A phase I study of the EZH2 inhibitor tazemetostat in pediatric subjects with relapsed or refractory INI1-negative tumors or synovial sarcoma.
First Author: Susan N. Chi
Poster
2022 ASCO Annual Meeting
Update on phase 1 study of tazemetostat, an enhancer of zeste homolog 2 inhibitor, in pediatric patients with relapsed or refractory integrase interactor 1–negative tumors.
First Author: Susan N. Chi
Poster
2020 ASCO Virtual Scientific Program
Phase I study of tazemetostat, an enhancer of zeste homolog-2 inhibitor, in pediatric pts with relapsed/refractory integrase interactor 1-negative tumors.
First Author: Susan N. Chi
Poster
2023 ASCO Annual Meeting
HH2853, an EZH1/2 inhibitor, in patients with epithelioid sarcoma: Preliminary results from the phase 1 part of a first-in-human phase I/II study.
First Author: Zhengfu Fan